Steward Partners Investment Advisory LLC Buys 1,463 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Steward Partners Investment Advisory LLC boosted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 12.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,590 shares of the company’s stock after purchasing an additional 1,463 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Cellebrite DI were worth $299,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in shares of Cellebrite DI by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company’s stock valued at $7,202,000 after acquiring an additional 75,092 shares during the last quarter. Telemark Asset Management LLC bought a new position in shares of Cellebrite DI during the 3rd quarter worth about $6,736,000. Two Sigma Advisers LP lifted its position in Cellebrite DI by 9.8% in the 3rd quarter. Two Sigma Advisers LP now owns 1,341,100 shares of the company’s stock valued at $22,584,000 after acquiring an additional 120,000 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in Cellebrite DI by 65.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company’s stock valued at $3,473,000 after acquiring an additional 62,320 shares in the last quarter. Finally, State Street Corp lifted its position in Cellebrite DI by 7.3% in the 3rd quarter. State Street Corp now owns 443,700 shares of the company’s stock valued at $7,472,000 after acquiring an additional 30,052 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on CLBT. Lake Street Capital lifted their target price on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. JPMorgan Chase & Co. lifted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Monday. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Stock Down 1.9 %

Cellebrite DI stock opened at $17.28 on Friday. The company has a market capitalization of $3.56 billion, a PE ratio of -12.43, a P/E/G ratio of 4.27 and a beta of 1.53. The firm has a fifty day simple moving average of $21.49 and a two-hundred day simple moving average of $19.68. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.